We attract distinguished and experienced industry professionals.
Our Scientific Advisory Board (SAB) works closely with the M6P Therapeutics’ leadership team to further advance research and development of the company’s innovative pipeline of lysosomal storage disorders (LSDs). By combining the substantial expertise of the SAB with the expertise of the company’s internal R&D team in enzyme replacement therapies and gene therapies, M6P Therapeutics is well positioned to rapidly advance its deep pipeline of LSD programs.
Stuart Kornfeld
Washington University. Co-Founder, M6PT & Chair, SAB
Nancy Dahms
Medical College of Wisconsin
Gregory Enns
Stanford School of Medicine
Mark Sands
Washington University
Anna Tylki-Szymanska
Children's Memorial Health Institute, Warsaw, Poland
Raymond Wang
University of California, Irvine School of Medicine
Stuart Kornfeld
Washington University. Co-Founder, M6PT & Chair, SAB
Stuart Kornfeld, co-founder of M6PT, the chairman of its SAB, and is a professor in the Department of Medicine and the Department of Biochemistry and Molecular Biophysics at Washington University Medical School. His lab discovered the mechanism whereby lysosomal enzymes acquire mannose 6-phosphate. Dr. Kornfeld has devoted decades to understanding mannose 6-phosphate and is considered the leading expert on this substance. He has advised multiple companies working on lysosomal storage disorders. He is a member of the National Academy of Sciences.
Nancy Dahms
Medical College of Wisconsin
Nancy Dahms, PhD, is a Professor of Biochemistry at the Medical College of Wisconsin. She received her doctorate degree from Johns Hopkins University School of Medicine where she studied site-specific N-glycosylation. As a postdoctoral fellow at Washington University School of Medicine, she isolated and characterized cDNA clones for the mannose 6-phosphate receptors involved in targeting lysosomal enzymes to the lysosome. A glycobiologist and biochemist, Dr. Dahms investigates glycan-binding proteins in the secretory pathway. Her research has defined the molecular basis for the recognition of lysosomal enzymes by the mannose 6-phosphate receptors. Dr. Dahms has developed a rat model for Fabry disease to aid in revealing pathogenic mechanisms of this common LSD.
Gregory Enns
Stanford School of Medicine
Gregory Enns, MD, is a Professor of Pediatrics and Genetics at the Lucile Salter Packard Children’s Hospital Stanford School of Medicine. Dr. Enns’ research interests include novel means of diagnosing and treating mitochondrial disorders, with an emphasis on antioxidant therapy, lysosomal disorders, and newborn screening by tandem mass spectrometry. His current pursuits include the analysis of glutathione and antioxidant status in patients who have mitochondrial disorders and the development of new techniques for diagnosing these conditions.
Mark Sands
Washington University
Mark S. Sands, PhD, is a Professor in the Departments of Medicine and Genetics at Washington University School of Medicine in St. Louis. Dr. Sands received his PhD in Molecular Pharmacology from the State University of New York at Stony Brook. He was a postdoctoral fellow at The Jackson Laboratory (Bar Harbor, ME) and at the University of Pennsylvania School of Veterinary Medicine before joining the faculty at Washington University School of Medicine. The goals of Dr. Sands laboratory are to better understand the underlying pathogenesis and developing effective therapies for inherited childhood diseases, specifically LSDs. A major focus of his group is to determine the safety and efficacy of adeno-associated viral gene transfer vectors for the treatment of both the CNS and systemic manifestations of these diseases. In addition, his group has developed lentiviral-mediated hematopoietic stem cell-directed gene therapy approaches, as well as small molecule drugs, and more recently rational combinations of these approaches. The primary diseases that Dr. Sands studies are mucopolysaccharidosis type VII (MPS VII), Krabbe disease, and Infantile Neuronal Ceroid Lipofuscinosis.
Anna Tylki-Szymanska
Children's Memorial Health Institute, Warsaw, Poland
Anna Tylki-Szymanska, MD, is a Professor, Department of Pediatrics and Pediatric Metabolic and Genetic Medicine at the Children’s Memorial Health Institute, Department of Metabolic Diseases in Warsaw, Poland. In the field of metabolic diseases, Prof. Tylki-Szymańska’s interests are focused mainly on lysosomal diseases. She has specialized for 30 years at the Department of Metabolic Diseases, which is the only referral center in Poland for inborn errors of metabolism. Prof. Tylki-Szymańska’s research interests are directed particularly on neurometabolic and neurodevelopmental diseases. She is especially interested in developing diagnostic assays and new approaches for the treatment of lysosomal diseases. She was a principal investigator for the recombinant enzyme replacement clinical trials for Gaucher, Fabry, MPS II and substrate inhibition therapy trials for MPS III, LAL deficiency and Gaucher disease. Prof. Tylki-Szymańska is a winner of the Order of the Smile. Order of the Smile is an international award given by children, to adults distinguished in their love, care, and aid for children.
Raymond Wang
University of California, Irvine School of Medicine
Raymond Wang, MD, is the Director of the Multidisciplinary Lysosomal Storage Disorder Program at CHOC Children’s, Associate Professor, Pediatrics, UC, Irvine School of Medicine. Dr. Wang is also a board-certified clinical geneticist and biochemical genetics specialist. He is investigating the role of inflammation and the innate immune system, triggered by arterial lysosomal storage, in promoting MPS cardiovascular disease, and identifying novel therapeutic methods to address treatment-refractory cardiovascular disease in MPS. He also actively works on other research projects related to Niemann-Pick C Disease, Pompe, Hunter, and Sanfillipo Syndrome.